Symbol
| IKBKE
| contributors: mct/shn - updated : 19-01-2022
|
HGNC name
| inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
|
HGNC id
| 14552
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
| amplification
| --over
|  
|
in breast cancer cell lines and patient-derived tumors | tumoral
|  
|  
| --over
|  
|
in breast cancer, ovarian cancer and prostate cancer | tumoral
|  
|  
| --over
|  
|
in glioma and contributes to resistance of glioma cells to apoptosis via activating NFKB | constitutional
|  
|  
| --low
|  
|
in SLE patients compared with healthy controls | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
| a possible therapeutic target for obesity, insulin resistance and diabetes |
|
System | Type | Disorder | Pubmed |
cancer | | | |
therapeutic target for cancer intervention | miscelleaneous | pain | | |
may be useful as a therapeutic target in the treatment of inflammatory pain | cancer | | | |
MCCK1 is an IKBKE inhibitor with anti-tumor activity and could be a potential anti-cancer agent for patients with tumors over expressing IKBKE |
| | |
| mice lacking IKKepsilon produce normal amounts of IFNbeta but are hypersusceptible to viral infection |